{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:51:53Z","timestamp":1785581513096,"version":"3.56.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijbiomac.2024.138369","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T17:35:57Z","timestamp":1733333757000},"page":"138369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Molecular insights into the aspartate protease Plasmepsin II activity inhibition by fluoroquinolones: A pathway to antimalarial drug development"],"prefix":"10.1016","volume":"285","author":[{"given":"Sadaf Fatima","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusri","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinjan","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2024.138369_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2958.2008.06407.x","article-title":"Reverse genetics screen identifies six proteins important for malaria development in the mosquito","volume":"70","author":"Ecker","year":"2008","journal-title":"Mol. Microbiol."},{"issue":"6906","key":"10.1016\/j.ijbiomac.2024.138369_bb0010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature01097","article-title":"Genome sequence of the human malaria parasite plasmodium falciparum","volume":"419","author":"Gardner","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.138369_bb0015","doi-asserted-by":"crossref","DOI":"10.1006\/expr.1997.4225","article-title":"Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite","volume":"87","author":"Westling","year":"1997","journal-title":"Exp. Parasitol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.138369_bb0020","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2174\/0929867033457674","article-title":"Inhibitors of the plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents","volume":"10","author":"Boss","year":"2003","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.138369_bb0025","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1432-1033.1997.00552.x","article-title":"Expression and characterization of plasmepsin I from plasmodium falciparum","volume":"244","author":"Moon","year":"1997","journal-title":"Eur. J. Biochem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.138369_bb0030","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2174\/138920211797248565","article-title":"Proteases in malaria parasites - a phylogenomic perspective","volume":"12","author":"Cai","year":"2011","journal-title":"Curr. Genomics"},{"issue":"23","key":"10.1016\/j.ijbiomac.2024.138369_bb0035","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.2174\/1568026619666181130133548","article-title":"Antimalarials: review of plasmepsins as drug targets and HIV protease inhibitors interactions","volume":"18","author":"Miller Iii","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.138369_bb0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijantimicag.2017.04.006","article-title":"Targeting the active sites of malarial proteases for antimalarial drug discovery: approaches, progress and challenges","volume":"50","author":"Roy","year":"2007","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.138369_bb0045","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.173.4.961","article-title":"Hemoglobin degradation in the human malaria pathogen plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease","volume":"173","author":"Goldberg","year":"1991","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.138369_bb0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0166-6851(96)02651-5","article-title":"Kinetic analysis of plasmepsins I and II aspartic proteases of the plasmodium falciparum digestive vacuole","volume":"79","author":"Luker","year":"1996","journal-title":"Mol. Biochem. Parasitol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.138369_bb0055","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1110\/ps.8.10.2001","article-title":"Active site specificity of plasmepsin II","volume":"8","author":"Westling","year":"1999","journal-title":"Protein Sci."},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.138369_bb0060","doi-asserted-by":"crossref","DOI":"10.1021\/bi0117549","article-title":"Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target","volume":"41","author":"Nezami","year":"2002","journal-title":"Biochemistry"},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.138369_bb0065","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1021\/acs.jmedchem.9b01622","article-title":"Plasmepsin inhibitors in antimalarial drug discovery: medicinal chemistry and target validation (2000 to present)","volume":"63","author":"Cheuka","year":"2020","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.138369_bb0070","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1021\/jm100233b","article-title":"Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents","volume":"53","author":"Gupta","year":"2010","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ijbiomac.2024.138369_bb0075","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/febs.14598","article-title":"Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins - biochemical and structural insights","volume":"285","author":"Mishra","year":"2018","journal-title":"FEBS J."},{"issue":"23","key":"10.1016\/j.ijbiomac.2024.138369_bb0080","doi-asserted-by":"crossref","first-page":"10049","DOI":"10.1016\/j.bmc.2008.10.011","article-title":"Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin","volume":"16","author":"Hidaka","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.138369_bb0085","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1021\/jm980641t","article-title":"Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II","volume":"42","author":"Haque","year":"1999","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.138369_bb0090","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.bmcl.2013.01.128","article-title":"Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening","volume":"23","author":"Song","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.138369_bb0095","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbapap.2011.04.008","article-title":"Structural studies of vacuolar plasmepsins","volume":"1824","author":"Bhaumik","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.fitote.2014.01.017","article-title":"Dietary flavonoids fisetin and myricetin: dual inhibitors of plasmodium falciparum falcipain-2 and plasmepsin II","volume":"94","author":"Jin","year":"2014","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0105","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1107\/S2053230X15022049","article-title":"Structures of plasmepsin II from plasmodium falciparum in complex with two hydroxyethyl amine-based inhibitors","volume":"71","author":"Recacha","year":"2015","journal-title":"Acta Crystallogr. F: Struct. Biol. Commun."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0110","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.2147\/DDDT.S265602","article-title":"Recent progress in the development of new antimalarial drugs with novel targets","volume":"14","author":"Belete","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0115","series-title":"Recent Advances in Antimalarial Drug Discovery-Challenges and Opportunities","author":"Imrat","year":"2021"},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0120","series-title":"Drugs in Development for Malaria","first-page":"861","volume":"78","author":"Elizabeth","year":"2018"},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.138369_bb0125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5897\/AJPPX12.015","article-title":"Antimalarial drugs: mode of action and status of resistance","volume":"7","author":"Saifi","year":"2012","journal-title":"Afr. J. Pharm. Pharmacol"},{"issue":"11","key":"10.1016\/j.ijbiomac.2024.138369_bb0130","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJM199609123351107","article-title":"The treatment of malaria","volume":"335","author":"White","year":"1996","journal-title":"NEJM"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.138369_bb0135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.apsb.2016.01.008","article-title":"Artemisinin anti-malarial drugs in China","volume":"6","author":"Guo","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0140","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.bmcl.2013.03.067","article-title":"Recent advances in malaria drug discovery","volume":"23","author":"Biamonte","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0145","first-page":"1","article-title":"DFT and docking studies of designed conjugates of noscapines & amp; repurposing drugs: promising inhibitors of main protease of SARS-CoV-2 and falcipan-2","volume":"3","author":"Kumar","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2022.120440","article-title":"Fluoroquinolone antibiotics: occurrence, mode of action, resistance, environmental detection, and remediation - A comprehensive review","volume":"315","author":"Bhatt","year":"2022","journal-title":"Environ. Pollut."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0155","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejps.2019.02.032","article-title":"Use of microdialysis for the assessment of fluoroquinolone pharmacokinetics in the clinical practice","volume":"131","author":"Tomas","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"15","key":"10.1016\/j.ijbiomac.2024.138369_bb0160","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.3390\/molecules29153538","article-title":"Recent development of fluoroquinolone derivatives as anticancer agents","volume":"29","author":"Nowakowska","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0165","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ejmech.2018.01.080","article-title":"Fluoroquinolone derivatives and their anti-tubercular activities","volume":"146","author":"Fan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.138369_bb0170","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone antibiotics","volume":"10","author":"Pham","year":"2019","journal-title":"Med. Chem. Comm."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.138369_bb0175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W","article-title":"Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects","volume":"16","author":"Gootz","year":"1996","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejmech.2019.01.017","article-title":"Quinolone hybrids and their anti-cancer activities: an overview","volume":"165","author":"Gao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejmech.2018.01.078","article-title":"Ciprofloxacin derivatives and their antibacterial activities","volume":"146","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0190","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bioorg.2017.09.015","article-title":"Application of the Morita-Baylis-Hillman reaction in the synthesis of 3-[(N-cycloalkylbenzamido) methyl]-2-quinolones as potential HIV-1 integrase inhibitors","volume":"75","author":"Sekgota","year":"2017","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.138369_bb0195","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1021\/jm401362f","article-title":"The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors","volume":"57","author":"Manfroni","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.138369_bb0200","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2174\/0929867323666151223095839","article-title":"A \u201cdouble-edged\u201d scaffold: antitumor power within the antibacterial quinolone","volume":"23","author":"Bisacchi","year":"2016","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.138369_bb0205","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.bbagen.2016.01.026","article-title":"Competitive binding of anticancer drugs 5-fluorouracil and cyclophosphamide with serum albumin: calorimetric insights","volume":"1860","author":"Thoppil","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"19","key":"10.1016\/j.ijbiomac.2024.138369_bb0210","doi-asserted-by":"crossref","first-page":"10034","DOI":"10.1073\/pnas.93.19.10034","article-title":"Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from plasmodium falciparum","volume":"93","author":"Silva","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.138369_bb0215","first-page":"739","article-title":"Selective inhibitors of plasmepsin II from plasmodium falciparum based on pepstatin","volume":"34","author":"Rumsh","year":"2008","journal-title":"Bioorg. Khim."},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.138369_bb0220","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1074\/jbc.M412086200","article-title":"Distal substrate interactions enhance plasmepsin activity","volume":"280","author":"Istvan","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.138369_bb0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0166-6851(03)00119-1","article-title":"Food vacuole plasmepsins are processed at a conserved site by an acidic convertase activity in plasmodium falciparum","volume":"129","author":"Banerjee","year":"2003","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0230","article-title":"Expression, purification, and characterization of aspartic endopeptidases: plasmodium plasmepsins and \u201cshort\u201d recombinant human pseudo cathepsin","author":"Beyer","year":"2004","journal-title":"Curr. Protoc. Protein Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.138369_bb0235","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0014-5793(94)00940-6","article-title":"High-level expression and characterization of Plasmepsin II, an aspartic proteinase from plasmodium falciparum","volume":"352","author":"Hill","year":"1994","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.138369_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/0471140864.ps0524s61","article-title":"Strategies to optimize protein expression in E. coli","volume":"5","author":"Francis","year":"2010","journal-title":"Curr. Protoc. Protein Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.138369_bb0245","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/2193-1801-2-89","article-title":"Production of soluble eukaryotic recombinant proteins in E. coli is favored in early log-phase cultures induced at low temperature","volume":"2","author":"San-Miguel","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0250","article-title":"Tumor-targeted liposomes with platycodin D2 promote apoptosis in colorectal cancer","volume":"22","author":"Cho","year":"2023","journal-title":"Mater. Today Bio."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.138369_bb0255","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.3390\/ijms24043632","article-title":"The formation of morphologically stable lipid nanocarriers for glioma therapy","volume":"24","author":"Pavlov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0260","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejmech.2015.03.049","article-title":"New paradigm of an old target: an update on structural biology and current progress in drug design towards plasmepsin II","volume":"95","author":"Dan","year":"2015","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.138369_bb0265","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/med.20082","article-title":"Plasmepsins as potential targets for new antimalarial therapy","volume":"26","author":"Ersmark","year":"2006","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.ijbiomac.2024.138369_bb0270","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/jac\/dkp449","article-title":"In vitro selection of plasmodium falciparum drug-resistant parasite lines","volume":"65","author":"Nzila","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0275","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003495-199958002-00006","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"58","author":"Turnidge","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0280","doi-asserted-by":"crossref","unstructured":"Drusano, George et al. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clinical Microbiology and Infection. 4 2S27 - 2S41.","DOI":"10.1111\/j.1469-0691.1998.tb00692.x"},{"key":"10.1016\/j.ijbiomac.2024.138369_bb0285","doi-asserted-by":"crossref","DOI":"10.1592\/phco.21.16.233S.33992","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"21","author":"Rodvold","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.ijbiomac.2024.138369_bb0290","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024091803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024091803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T02:08:42Z","timestamp":1738462122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024091803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":58,"alternative-id":["S0141813024091803"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.138369","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular insights into the aspartate protease Plasmepsin II activity inhibition by fluoroquinolones: A pathway to antimalarial drug development","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.138369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"138369"}}